WaveMan
WaveMan · Company
DTIL · Precision Biosciences Inc
> Search tickers & screens ⌘K
LIVE
← All companies

DTIL Precision Biosciences (DTIL) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Biological products, (no diagnostic substances) · CIK 0001357874
Quote by TradingView
Cluster · 3 insiders
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
64
13F, latest reported quarter
Conversions, 180 days
5
Codes C/M, not in net · no price filed

What the filings say about DTIL

Insiders, 180 days
+$29.5K net bought
3 buyers

Precision Biosciences insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, PRECISION BIOSCIENCES INC insiders bought a net $29.5K of stock across 66 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Frankel Stanley
Director
BUY
2026-09-30 SECtraded 2026-09-28
1,000
$6.0K
+1.3%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on Dec 16, 2025.
  • +7.2% median (+7.2% mean) 90-day return after 2 previous buys.
  • The trade is 2.4% of the 41,478 shares held after it.
  • 2 other insiders bought within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Frankel Stanley bought about $6.0K of DTIL on Sep 28, 2026; 2 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.
Brown Melinda
Director
BUY
2026-09-29 SECtraded 2026-09-25
1,135
$7.1K
+2.4%
Context
  • 5 earlier Form 4 trades (code P or S) here by this insider (5 buys), the last on Dec 15, 2025.
  • +0.9% median (+6.5% mean) 90-day return after 5 previous buys.
  • The trade is 2.5% of the 45,481 shares held after it.
  • 2 other insiders bought within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Brown Melinda bought about $7.1K of DTIL on Sep 25, 2026; 2 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.
Germano Geno J
Director
BUY
2026-09-29 SECtraded 2026-09-25
2,609
$16.4K
+2.4%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Dec 16, 2025.
  • +12.0% median (+10.6% mean) 90-day return after 3 previous buys.
  • The trade is 5.5% of the 47,492 shares held after it.
  • 2 other insiders bought within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Germano Geno J bought about $16.4K of DTIL on Sep 25, 2026, the largest insider purchase at the company since 2025; 2 other insiders bought within 30 days and 64 funds added in the latest 13F quarter.
Amoroso Michael
President and CEO
SELL
2026-02-19 SECtraded 2026-02-18
20,559
$78.9K
+69.1%
Context
  • 10 earlier Form 4 trades (code P or S) here by this insider (10 sales), the last on Jan 22, 2026.
  • The trade is 8.4% of the 243,392 shares held after it.
  • 3 other insiders sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Amoroso Michael sold about $78.9K of DTIL on Feb 18, 2026; 3 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
Kelly John Alexander
Chief Financial Officer
SELL
2026-02-19 SECtraded 2026-02-18
8,149
$31.3K
+69.1%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (8 buys, 3 sales), the last on Jan 21, 2026.
  • -17.3% median (-20.3% mean) 90-day return after 8 previous buys.
  • The trade is 6.5% of the 125,883 shares held after it.
  • 3 other insiders sold within 30 days.
  • 64 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Financial Officer Kelly John Alexander sold about $31.3K of DTIL on Feb 18, 2026; 3 other insiders sold within 30 days and 64 funds added in the latest 13F quarter.
66 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 61 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net +$29.5K over 180 days
+$29.5K over 90 days
more than 70% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
64 funds bought in last quarter
more than 53% of Pharma & Biotech
Revenue
-50.1% year over year
below 80% of Pharma & Biotech
Margin
-133.4% net margin
below 60% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
9.9% of the float short (float per yahoo 2026-10-26) · 8.8 days to cover · settled 2026-09-30
more than 68% of Pharma & Biotech
What changed in the last 30 days
Sep 30Director Frankel Stanley bought $6.0K (Sep 28)
Sep 29Director Germano Geno J bought $16.4K (Sep 25)
Sep 29Director Brown Melinda bought $7.1K (Sep 25)

Watch DTIL

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-7.5%12M
-48%-21%+6%+34%2025-102025-122026-022026-042026-062026-082026-10 2026-01-22 · Amoroso Michael sold $145.1K2026-02-18 · Amoroso Michael sold $78.9K2026-01-21 · Kelly John Alexander sold $61.3K2026-01-21 · SMITH J. JEFFERSON sold $41.1K2026-01-21 · Scimeca Dario sold $35.7K2026-02-18 · Kelly John Alexander sold $31.3K2025-11-03 · Amoroso Michael sold $22.1K2026-02-18 · Scimeca Dario sold $18.9K2026-02-18 · SMITH J. JEFFERSON sold $18.9K2026-09-25 · Germano Geno J bought $16.4K2025-12-16 · Germano Geno J bought $14.2K2025-12-16 · Frankel Stanley bought $12.7K2025-11-03 · Kelly John Alexander sold $8.5K2026-09-25 · Brown Melinda bought $7.1K2025-12-15 · Brown Melinda bought $6.9K2026-09-28 · Frankel Stanley bought $6.0K2025-11-03 · Scimeca Dario sold $4.3K
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns DTIL: institutional holders (13F)

13F holdings, latest reported quarter
Aberdeen Group plc
2,230,178 sh
$17.5M
Bleichroeder LP
2,018,190 sh
$15.9M
Lynx1 Capital Management LP
1,900,932 sh
$14.9M
Octagon Capital Advisors LP
1,350,000 sh
$10.6M
BOOTHBAY FUND MANAGEMENT, LLC
1,346,004 sh
$10.6M

Congress trades in DTIL

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

DTIL planned insider sales (Form 144)

No planned-sale notices
No insider has filed to sell. Watch this after a run-up.

DTIL mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Jacob Discovery Fund
$363.1K position · as of 2026-05-31
2.3%
Meridian Contrarian Fund
$2.2M position · as of 2026-06-30
0.3%
NVIT GS Small Cap Equity Insights Fund
$115.1K position · as of 2026-06-30
0.1%
Goldman Sachs Variable Insurance Trust Small Cap Equity Insights Fund
$121.5K position · as of 2026-06-30
0.1%
LVIP JPMorgan Small Cap Core Fund
$103.9K position · as of 2026-06-30
0.0%
JPMorgan U.S. Small Company Fund
$480.1K position · as of 2026-06-30
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 3 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
3
Phase 1
1 active
1
Not applicable
1 active
2
Multi-phase
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $29.5K bought by insiders over 180 days, 64 funds added last quarter. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

DTIL financials

Revenue growth
-50.1%
XBRL, annual
Net margin
-133.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$45.1M
four quarters, 2025-07-01 to 2026-06-30
Net margin, TTM
-117.0%
net income over revenue, 2025-07-01 to 2026-06-30
Free cash flow, TTM
-$51.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.49x
long-term debt only, 2023-03-31 (39 months older than the period end); equity 2026-06-30
Cash flow to debt
-2.33x
TTM operating cash flow over long-term debt only, 2023-03-31 (39 months older than the period end)
Return on equity
-132.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-44.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-34.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$113.1M
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2023-03-31 (39 months older than the period end), minus cash 2026-06-30
FCF yield
-29.4%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Revenue$34.3M$68.7M$48.7M$25.1M
Operating income-$52.1M-$26.2M-$43.7M-$62.3M
Net income-$45.7M$7.2M-$61.3M-$111.6M
EPS (diluted)-3.561.04-15.96-38.10
Operating cash flow-$65.8M-$58.4M-$84.1M-$45.8M
Cash$110.8M$85.9M$116.7M$189.6M
Long-term debtn/an/an/a$22.2M
SEC XBRL, fiscal years, as known on 2026-10-28

DTIL Stock Sonar score 6/7 axes

Find similar shapesCompare

DTIL ranks highest on insider conviction (79th percentile) and risk and compliance (61st), and lowest on growth (20th), among Pharma & Biotech peers.

ProfitHealthGrowthInsidersInstitutionsRisk
Profitability
46
Inputs
  • Return on equity-132.9% · 26 pct, sector of 545
  • Return on assets-44.9% · 48 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-34.0% · 66 pct, sector of 576
Financial health
37
Inputs
  • Debt to equity0.49x · 32 pct, sector of 352
  • Cash flow to debt-2.33x · 42 pct, sector of 371
Growth
20
Inputs
  • Revenue growth, YoY-50.1% · 20 pct, sector of 505
  • Backlog growth, YoYno backlog line filed, or no year-earlier backlog
Insider conviction
79
Inputs
  • Net Form 4 buying (codes P and S), 180d$30K · 70 pct, sector of 428
  • Insider buyers, 180d3 · 89 pct, sector of 437
Institutional and government
53
Inputs
  • Funds adding, latest quarter64 · 53 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
61
Inputs
  • Short interest, % of float+9.9% · 40 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-K+5.0% · 82 pct, sector of 511
1 not measured: US patents
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

DTIL filings, in plain words

Are Precision Biosciences insiders buying or selling DTIL?

In the 180 days to 2026-10-28, Precision Biosciences insiders were net buyers, a net $29.5K across purchases and sales reported on Form 4, by 3 buyers.

Read the full summary

In the 180 days to 2026-10-28, Precision Biosciences insiders were net buyers of DTIL, a net $29.5K across purchases and sales reported on Form 4 by 3 buyers. 3 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies